Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Nat Med
; 29(10): 2570-2576, 2023 10.
Article
in En
| MEDLINE
| ID: mdl-37783970
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Anemia
/
Multiple Myeloma
Limits:
Humans
Language:
En
Journal:
Nat Med
Journal subject:
BIOLOGIA MOLECULAR
/
MEDICINA
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: